Background: Methylation of MGMT promoter has been identified as a favourable predictive factor ofbenefit from XRT/TMZ → TMZ. Patients with non-resectable glioblastoma (GBM) generally exhibit a poorprognosis, even after XRT/TMZ. Few data are available concerning the predictive value of MGMT promotermethylation in this population.Methods: This is an observational retrospective study in patients with malignant brain glioma, treatedbetween June 2008 and October 2011 and followed up until April 2012 at the Neurosurgery-Neurotraumatology Unit of the University Hospital of Parma and at the Neurosurgery Unit of IRCCS“ASMN” of Reggio Emilia, Italy. The medical records of an overall number of 174 patients with a newlydiagnosed GBM were reviewed. Volumetry analysis of the lesions was performed on pre- and post-operative neuroimaging by Voxar 3D Ebit AET software. The genetic characterization was performedon paraffin embedded tissue from all resected tumours. Isolation of nucleic acids, bisulfite modifica-tion of DNA, methylation-specific PCR and sequencing analyses were done mainly on fresh tissue frombiopsy withdrawals. Within 3–4 weeks after either biopsy or surgery, patients were assigned to receiveXRT/TMZ → TMZ: treatment included XRT (60 Gy in 30 fractions)/TMZ (daily dose of 75 mg/m2)/TMZ(150–200 mg/m2per day for 5 days of every 28-day cycle).
Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy / Iaccarino, C; Orlandi, E; Ruggeri, F; Nicoli, D; Torricelli, F; Maggi, M; Cerasti, D; Pisanello, A; Pedrazzi, G; Froio, E; Crafa, P; D’Abbiero, N; Michiara, M; Ghadirpour, R; Servadei, F. - In: CLINICAL NEUROLOGY AND NEUROSURGERY. - ISSN 0303-8467. - 132:(2015), pp. 1-8. [10.1016/j.clineuro.2015.01.029]
Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy
Iaccarino C;
2015
Abstract
Background: Methylation of MGMT promoter has been identified as a favourable predictive factor ofbenefit from XRT/TMZ → TMZ. Patients with non-resectable glioblastoma (GBM) generally exhibit a poorprognosis, even after XRT/TMZ. Few data are available concerning the predictive value of MGMT promotermethylation in this population.Methods: This is an observational retrospective study in patients with malignant brain glioma, treatedbetween June 2008 and October 2011 and followed up until April 2012 at the Neurosurgery-Neurotraumatology Unit of the University Hospital of Parma and at the Neurosurgery Unit of IRCCS“ASMN” of Reggio Emilia, Italy. The medical records of an overall number of 174 patients with a newlydiagnosed GBM were reviewed. Volumetry analysis of the lesions was performed on pre- and post-operative neuroimaging by Voxar 3D Ebit AET software. The genetic characterization was performedon paraffin embedded tissue from all resected tumours. Isolation of nucleic acids, bisulfite modifica-tion of DNA, methylation-specific PCR and sequencing analyses were done mainly on fresh tissue frombiopsy withdrawals. Within 3–4 weeks after either biopsy or surgery, patients were assigned to receiveXRT/TMZ → TMZ: treatment included XRT (60 Gy in 30 fractions)/TMZ (daily dose of 75 mg/m2)/TMZ(150–200 mg/m2per day for 5 days of every 28-day cycle).File | Dimensione | Formato | |
---|---|---|---|
2015 Iaccarino CLINNEURNS MGMT prognostic factor.pdf
Accesso riservato
Dimensione
961.11 kB
Formato
Adobe PDF
|
961.11 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris